Search

Displaying results 6071 - 6080 of 10000 in total
  1. Drug

    Edonerpic

    go.drugbank.com/drugs/DB05938
    Investigational

    Edonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.

  2. Drug

    Transcrocetinate

    go.drugbank.com/drugs/DB05974
    Investigational

    Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    Meclocycline

    go.drugbank.com/drugs/DB13092
    Investigational

    Meclocycline is under investigation in clinical trial NCT00385515 (Efficacy of SNX-1012 in the Treatment of Oral Mucositis) .

  4. Drug

    Sapacitabine

    go.drugbank.com/drugs/DB06365
    Investigational

  5. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  6. Drug

    Caldaret

    go.drugbank.com/drugs/DB06231
    Investigational

  7. Drug

    Gavorestat

    go.drugbank.com/drugs/DB16707
    Investigational

    Gavorestat is under investigation in clinical trial NCT04902781 (Clinical Benefit, Safety, PK and PD Study of AT-007 in Pediatric Subjects With Classic Galactosemia).

    Synonyms: AT-007
  8. Drug

    Disitamab vedotin

    go.drugbank.com/drugs/DB17208
    Investigational

    Disitamab vedotin is an antibody-drug conjugate drug targeting human epidermal growth factor receptor 2 (HER2). It is currently being investigated for cancers.[A254721]

  9. Drug

    MGN-4893

    go.drugbank.com/drugs/DB17338
    Experimental

    MGN-4893 is an inhibitor of microRNA-451. In February 2011, it was granted FDA orphan designation for the treatment of polycythemia vera.[L47356]

  10. Drug

    Ixmyelocel-T

    go.drugbank.com/drugs/DB17601
    Investigational

    Ixmyelocel-T is an expanded, autologous multicellular therapy cultured from bone-marrow mononuclear cells. Developed by Vericel Corporation, it is being investigated for cardiomyopathy.